Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 |
| NCT05376553 | Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | enrolling by invitation | Phase 1 | 24 | Krzysztof MisiukiewiczOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials